Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neo Derm Group Sets Fooprint On Mainland China

This article was originally published in PharmAsia News

Executive Summary

Neo Derm Group, Hong Kong's largest cosmetic dermatology company, has invested RMB 20 million ($2.9 million) to set up its first mainland medical cosmetic center in Shanghai. The cosmetic center, unlike a beauty shop, is a professional dermatology clinic that has been granted a medical institution practice license by Shanghai Municipal Health Bureau. The beauty industry has become one of China's five-largest consumer sectors, with revenue hitting RMB 200 billion ($29.25 billion) in 2006 and expected to double in 2011. Neo Derm Group said that despite the challenging economic situation it has confidence in China's medical cosmetic market thanks to little competition there. The group plans to get listed on the Hong Kong Stock Exchange and set up three to five centers annually in the territory. It will also develop the China and Southeast Asia market. (Click here for more - Chinese Language)

You may also be interested in...

L’Oreal Names CEO To Follow Agon; ELC And Coty Appoint Digital Leadership; Executive News In Brief

Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts